BioWorld-International-2006-10-04
ProStrakan's Agreement With Novartis Could Reach $140M
ProStrakan's Agreement With Novartis Could Reach $140M
LONDON - ProStrakan Group plc sealed a deal with a headline value of $140 million under which Novartis AG will develop antibody treatments for bone-related diseases using a ProStrakan target. (BioWorld International)

